|
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|
The New England journal of medicine |
2016 |
239.8 |
4,291 |
|
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|
The New England journal of medicine |
2018 |
214.1 |
5,493 |
|
Reduction in Late Mortality among Five-Year Survivors of Childhood Cancer
|
The New England journal of medicine |
2016 |
138.1 |
568 |
|
Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)
|
Lancet (London, England) |
2015 |
133.5 |
2,649 |
|
Inotuzumab Ozogamicin Versus Standard Care for Acute Lymphoblastic Leukemia
|
The New England journal of medicine |
2016 |
132.3 |
1,345 |
|
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
|
The New England journal of medicine |
2018 |
121.1 |
2,636 |
|
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
|
Lancet (London, England) |
2015 |
103.4 |
2,916 |
|
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|
The New England journal of medicine |
2016 |
100.4 |
1,864 |
|
Leisure-time physical activity and risk of 26 types of cancer in 1.44 million adults
|
JAMA internal medicine |
2016 |
87.9 |
1,460 |
|
ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
|
Biology of blood and marrow transplantat |
2019 |
80.1 |
3,255 |
|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|
The New England journal of medicine |
2015 |
78.4 |
1,541 |
|
Functional Genomic Landscape of Acute Myeloid Leukemia
|
Nature |
2018 |
72.8 |
1,426 |
|
Efficacy and Biological Correlates of Response in a Phase 2 Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
|
Cancer discovery |
2016 |
69.2 |
1,043 |
|
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
|
The New England journal of medicine |
2018 |
68.5 |
939 |
|
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
|
Science translational medicine |
2015 |
68.3 |
1,714 |
|
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
|
Journal of clinical oncology : official |
2016 |
68.1 |
929 |
|
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
|
The New England journal of medicine |
2016 |
65.6 |
780 |
|
Prediction of acute myeloid leukaemia risk in healthy individuals
|
Nature |
2018 |
64.6 |
852 |
|
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|
The New England journal of medicine |
2019 |
62.3 |
724 |
|
CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
|
Nature medicine |
2018 |
57.3 |
1,327 |
|
Mutations driving CLL and their evolution in progression and relapse
|
Nature |
2015 |
56.4 |
1,059 |
|
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
|
Nature medicine |
2018 |
52.0 |
1,230 |
|
A causal mechanism for childhood acute lymphoblastic leukaemia
|
Nature reviews. Cancer |
2018 |
50.6 |
531 |
|
Mechanisms of resistance to CAR T cell therapy
|
Nature reviews. Clinical oncology |
2019 |
48.5 |
947 |
|
NUDT15 Polymorphisms Alter Thiopurine Metabolism and Hematopoietic Toxicity
|
Nature genetics |
2016 |
47.8 |
462 |
|
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|
The New England journal of medicine |
2016 |
47.8 |
589 |
|
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|
The New England journal of medicine |
2016 |
47.4 |
882 |
|
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem cell transplantation
|
Nature |
2019 |
47.4 |
588 |
|
Effect of Mutation Order on Myeloproliferative Neoplasms
|
The New England journal of medicine |
2015 |
46.6 |
566 |
|
Somatic mutations precede acute myeloid leukemia years before diagnosis
|
Nature medicine |
2018 |
45.6 |
610 |
|
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia
|
Cancer discovery |
2016 |
44.8 |
1,067 |
|
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
|
The New England journal of medicine |
2018 |
44.0 |
1,091 |
|
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
|
The New England journal of medicine |
2015 |
43.7 |
620 |
|
Rise and fall of subclones from diagnosis to relapse in Pediatric B-Acute Lymphoblastic Leukemia
|
Nature communications |
2015 |
43.4 |
358 |
|
Acute myeloid leukaemia
|
Lancet (London, England) |
2018 |
43.2 |
765 |
|
Etiology of Ibrutinib Discontinuation and Outcomes in Chronic Lymphocytic Leukemia Patients
|
JAMA oncology |
2015 |
38.6 |
574 |
|
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
|
Leukemia |
2018 |
38.1 |
544 |
|
Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
|
Cancer discovery |
2018 |
37.4 |
904 |
|
The mutational landscape of cutaneous T-cell lymphoma and Sézary syndrome
|
Nature genetics |
2015 |
35.3 |
370 |
|
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
|
Cancer discovery |
2019 |
34.7 |
565 |
|
Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors
|
Nature |
2018 |
34.4 |
930 |
|
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|
The New England journal of medicine |
2019 |
34.1 |
455 |
|
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia
|
Nature medicine |
2015 |
33.9 |
568 |
|
DNMT3A in haematological malignancies
|
Nature reviews. Cancer |
2015 |
33.9 |
512 |
|
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
|
Nature medicine |
2018 |
33.4 |
858 |
|
Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
|
JAMA |
2015 |
32.6 |
341 |
|
Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia
|
Cancer cell |
2019 |
32.5 |
842 |
|
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia
|
JAMA |
2015 |
32.4 |
274 |
|
Disruption of TET2 Promotes the Therapeutic Efficacy of CD19-targeted T-cells
|
Nature |
2018 |
32.4 |
843 |
|
Biological and Clinical Characteristics of Adolescent and Young Adult Cancers: Acute Lymphoblastic Leukemia, Colorectal Cancer, Breast Cancer, Melanoma and Sarcoma
|
Cancer |
2016 |
32.1 |
142 |
|
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
|
The lancet. Gastroenterology & hepatolog |
2019 |
31.4 |
218 |
|
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
|
The New England journal of medicine |
2019 |
31.0 |
263 |
|
Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche
|
Cell stem cell |
2016 |
30.9 |
531 |
|
Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
|
Science translational medicine |
2016 |
30.4 |
900 |
|
Genomic profiling of Sézary Syndrome identifies alterations of key T-cell signaling and differentiation genes
|
Nature genetics |
2015 |
30.0 |
321 |
|
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
|
Blood reviews |
2019 |
29.6 |
894 |
|
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
|
The Lancet. Oncology |
2015 |
29.5 |
366 |
|
Prospects for gene-engineered T cell immunotherapy for solid cancers
|
Nature medicine |
2016 |
29.0 |
359 |
|
Glucocorticoids and Cancer
|
Advances in experimental medicine and bi |
2015 |
27.9 |
207 |
|
The Changing Burden of Late Health Outcomes in Adult Survivors of Childhood Acute Lymphoblastic Leukemia: A Report from the St. Jude Lifetime Cohort Study
|
The Lancet. Haematology |
2019 |
27.3 |
142 |
|
Social Media and the Adolescent and Young Adult (AYA) patient with Cancer
|
Current hematologic malignancy reports |
2016 |
26.6 |
112 |
|
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomized, dose-escalation phase 1 study
|
The Lancet. Oncology |
2015 |
26.1 |
281 |
|
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
|
Leukemia |
2019 |
26.0 |
249 |
|
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
|
Nature |
2018 |
25.5 |
278 |
|
Inotuzumab Ozogamicin in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
|
Leukemia |
2019 |
25.3 |
204 |
|
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
|
The Lancet. Oncology |
2018 |
25.2 |
262 |
|
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
|
The Lancet. Oncology |
2019 |
25.1 |
282 |
|
Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: a Multicentre, Open-Label Phase 2 Trial
|
The Lancet. Oncology |
2018 |
25.0 |
376 |
|
Risk of Cancer in Children Conceived by Assisted Reproductive Technology
|
Pediatrics |
2016 |
24.0 |
62 |
|
Biological role and therapeutic potential of IDH mutations in cancer
|
Cancer cell |
2018 |
23.3 |
314 |
|
Clinical Utility of Sequential Minimal Residual Disease Measurements in the Context of Risk-based Therapy in Childhood Acute Lymphoblastic Leukemia: a Prospective Study
|
The Lancet. Oncology |
2015 |
22.5 |
207 |
|
The genetic basis and cell of origin of mixed phenotype acute leukaemia
|
Nature |
2018 |
22.4 |
362 |
|
The Association between Clinician-Based Common Terminology Criteria for Adverse Events (CTCAE) and Patient-Reported Outcomes (PRO): A Systematic Review
|
Supportive care in cancer : official jou |
2016 |
22.1 |
373 |
|
First Report of a Phase II Prospective Study of Combination of Hyper-CVAD with Ponatinib in Frontline Therapy of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
The Lancet. Oncology |
2015 |
21.9 |
278 |
|
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
|
Clinical cancer research : an official j |
2016 |
21.1 |
261 |
|
Complex Karyotype is a Stronger Predictor than Del(17p) for Inferior Outcome in Relapsed or Refractory CLL Patients Treated with Ibrutinib-Based Regimens
|
Cancer |
2015 |
20.8 |
247 |
|
TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL
|
Science translational medicine |
2015 |
20.2 |
207 |
|
Multiple Myeloma: 2018 update on Diagnosis, Risk-stratification and Management
|
American journal of hematology |
2018 |
20.1 |
200 |
|
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
|
Nature communications |
2015 |
20.0 |
252 |
|
EFFICACY OF RETINOIDS IN IKZF1-MUTATED BCR-ABL1 ACUTE LYMPHOBLASTIC LEUKEMIA
|
Cancer cell |
2015 |
19.6 |
215 |
|
Targeting Mutant BRAF with Vemurafenib in Relapsed or Refractory Hairy Cell Leukemia
|
The New England journal of medicine |
2015 |
19.0 |
339 |
|
Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia
|
Cell |
2016 |
19.0 |
479 |
|
Anxiety, Pain, and Nausea During the Treatment of Standard-Risk Childhood Acute Lymphoblastic Leukemia: A Prospective, Longitudinal Study From the Children’s Oncology Group
|
Cancer |
2016 |
19.0 |
106 |
|
Haematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3 -ITD Acute Myeloid Leukaemia in first complete remission
|
British journal of haematology |
2016 |
19.0 |
174 |
|
U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies
|
Nature cell biology |
2019 |
18.0 |
249 |
|
Silver nanoparticles: synthesis, properties, and therapeutic applications
|
Drug discovery today |
2015 |
17.9 |
952 |
|
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor Enasidenib
|
Nature medicine |
2018 |
17.8 |
195 |
|
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
|
Leukemia |
2018 |
17.4 |
174 |
|
Novel immunotherapies in lymphoid malignancies
|
Nature reviews. Clinical oncology |
2016 |
17.4 |
258 |
|
Growth Patterns During and After Treatment in Patients with Pediatric ALL: A Meta-Analysis
|
Pediatric blood & cancer |
2015 |
17.2 |
69 |
|
Genomics and drug profiling of fatal TCF3-HLF- positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
|
Nature genetics |
2015 |
17.2 |
250 |
|
Obesity and Metabolic Syndrome among Adult Survivors of Childhood Leukemia
|
Current treatment options in oncology |
2016 |
17.0 |
64 |
|
Dynamic risk profiling using serial tumor biomarkers for personalized outcome Prediction
|
Cell |
2019 |
16.7 |
228 |
|
Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
|
Leukemia |
2016 |
16.6 |
189 |
|
Emerging Cellular Therapies for Cancer
|
Annual review of immunology |
2019 |
16.6 |
392 |
|
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
|
The New England journal of medicine |
2018 |
16.5 |
462 |
|
Clonal evolution mechanisms in NT5C2 mutant relapsed acute lymphoblastic leukemia
|
Nature |
2018 |
16.3 |
113 |
|
Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse
|
Cancer research |
2016 |
16.2 |
165 |
|
Clinical Implications of Bone Marrow Adiposity
|
Journal of internal medicine |
2018 |
16.1 |
230 |
|
Pharmacological and protein profiling suggest venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia
|
Clinical cancer research : an official j |
2015 |
16.1 |
216 |